Cargando…

Editorial: Immunotherapy in Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Giuliani, Nicola, Malavasi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702966/ https://www.ncbi.nlm.nih.gov/pubmed/31475006 http://dx.doi.org/10.3389/fimmu.2019.01945

Ejemplares similares

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
por: Horenstein, Alberto L., et al.
Publicado: (2019)

Editorial: The Role of Microorganisms in Multiple Myeloma
por: Linares, Maria, et al.
Publicado: (2022)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
por: Alfarra, Helmi, et al.
Publicado: (2020)

In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma
por: Khalaf, Wafaa S., et al.
Publicado: (2019)

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma
por: Pisano, Michael, et al.
Publicado: (2021)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients
por: Shinde, Prajakta, et al.
Publicado: (2019)

Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
por: Fazzi, Rita, et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
por: Toscani, Denise, et al.
Publicado: (2018)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Editorial: Influenza Virus Vaccines and Immunotherapies
por: Kumar, Arun, et al.
Publicado: (2015)

Editorial: Targeting Metabolism in Cancer Immunotherapy
por: Roszik, Jason, et al.
Publicado: (2018)

Editorial: NKT Cells in Cancer Immunotherapy
por: Webb, Tonya J., et al.
Publicado: (2020)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Role of Galectins in Multiple Myeloma
por: Storti, Paola, et al.
Publicado: (2017)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Erratum: Editorial: NKT Cells in Cancer Immunotherapy
Publicado: (2020)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Editorial: Nanobody-based cancer immunotherapy and immunoimaging
por: Jafari, Mahdie, et al.
Publicado: (2023)

Editorial: Translational phenomics and its applications in immunotherapy
por: Fang, Hai, et al.
Publicado: (2023)

Editorial: Extracellular traps in cancer immunity and immunotherapy
por: Rahat, Michal A., et al.
Publicado: (2023)

Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023)

Editorial: NK cells in viral immunology and immunotherapy
por: Mulik, Sachin, et al.
Publicado: (2023)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Editorial: Heterologous Immunity: Implications and Applications in Vaccines and Immunotherapies
por: Singh, Shakti, et al.
Publicado: (2020)

Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms
por: Chandra, Janin, et al.
Publicado: (2022)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
por: Martin, Francisco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9ok7opr9a7fn2kvsgbes5qfvg